ArticlesBlog

Genitourinary cancer care at Sunnybrook – prostate, bladder, testis, kidney

Genitourinary cancer care at Sunnybrook – prostate, bladder, testis, kidney


The Edmund Odette Cancer Centre is the
sixth largest cancer centre in North America. The genitourinary cancer group is
one of the largest within this cancer centre. We have over fifty clinicians, scientists,
pathologists, radiation therapists, physicists and nurses within our team. Our goal is to provide innovative and
transformative cancer care to patients with prostate, kidney, bladder and testis cancer. Our clinicians, that consist of surgical
radiation and medical oncologists, take a comprehensive approach from diagnosis to
treatment to cure. We aim to provide state-of-the-art care
that applies our research findings and quickly translates them to the bedside to improve the delivery of better cancer care. Our research efforts in better
evaluating patients at risk for prostate cancer has led to develop our
internationally recognized online prostate cancer risk calculator. For years, we have used inaccurate blood test called PSA. We have developed a new tool to better
evaluate an individual’s risk for prostate cancer to better decide who needs a prostate biopsy. Most importantly, when the risk calculator indicates a
biopsy is needed, Sunnybrook is the first in Canada to provide rapid prostate biopsy
clinic. A patient will get their biopsy results
within seventy two hours of their biopsy and if cancer is unfortunately found
they’ll get immediate multidisciplinary cancer care from our team of specialists. If cancer treatment is necessary our
surgical and radiation facilities provide state-of-the-art treatment. Our methods in prostate bladder and
kidney surgery have attracted referrals from patients from all over Canada. Our radiation treatment approaches have
garnered international recognition and have been copied in several
countries. An important facet of our care team is our
research scientists. Although they are not directly involved
in patient care, it is these groups of people that act as catalysts for breakthroughs
in cancer care. Dr. Arun Seth heads our prostate cancer
research team in basic science. We have been working on prostate cancer
biomarkers for quite some time and trying to identify markers that will
distinguish prostate cancer with greater accuracy compared to what’s already available. So our research will be more
beneficial to prostate cancer patients because what we’re doing is identifying the gene
which can eventually be used to develop drugs, monitor the disease, as well as can be used as a diagnostic marker. That will eventually give us individualized treatment options. The strength of our research centre, because it’s a multi-disciplinary research team, includes oncologists, pathologists,
molecular biologists and surgeons. Every week we get the samples right from the surgeons and can analyze
in our lab right away. Our research is funded by government but we would like to see a lot
more funding because that way we can buy new equipment which will help us do our work better and analyze the
tumors in a better way. That’s what we want to see and will help us to provide better care for patients. As you can see, our GU group has a proven track
record in research accomplishments with several hundred peer reviewed publications,
national grants and leadership roles within prestigious national and
international oncology associations. Our accomplishments would not have been
possible without the generous gifts from patients, donors and friends. Now more than ever we need your support to continue our
excellence in providing cancer care.

Comment here